BACKGROUND: Enterobacter species have become increasingly important nosocomial pathogens. However, resistance to cephalosporins often complicates the treatment of Enterobacter infection. This study was conducted to evaluate the predictors of mortality and the impact of cephalosporin resistance on outcome in patients with Enterobacter bacteremia. METHODS: A total of 183 patients with Enterobacter bacteremia were retrospectively analyzed. Broad-spectrum cephalosporin resistance was defined as in vitro resistance to cefotaxime or ceftazidime. The main outcome measure was the 30-day mortality rate. RESULTS: Of 183 patients, 86 (47%) had bacteremia caused by broad-spectrum cephalosporin-resistant Enterobacter species, and their infections were classified as resistant. The 30-day mortality rate of patients with resistant infections (the resistant group) was significantly higher than that of patients with susceptible infections (the susceptible group) (33.7% vs. 18.6%; P=.021). When the 30-day mortality rates were compared according to the primary sites of infection and underlying conditions, the 30-day mortality rates of the resistant group were significantly higher than those of the susceptible group, in patients with an unknown primary site of infection, or in patients with septic shock. Multivariate analysis showed that broad-spectrum cephalosporin resistance was one of the independent risk factors associated with 30-day mortality (odds ratio [OR], 3.69; 95% confidence interval [CI], 1.01-13.52; P=.049). Presentation with septic shock and an increasing Acute Physiology and Chronic Health Evaluation II score were also independent risk factors for mortality (OR, 59.91 [95% CI, 14.93-240.15; P<.001] and 1.52 [95% CI, 1.24-1.86; P<.001], respectively). CONCLUSIONS: Broad-spectrum cephalosporin resistance adversely affects the outcome of patients with Enterobacter bacteremia, especially those with an unknown primary site of infection and those with septic shock.
BACKGROUND: Enterobacter species have become increasingly important nosocomial pathogens. However, resistance to cephalosporins often complicates the treatment of Enterobacter infection. This study was conducted to evaluate the predictors of mortality and the impact of cephalosporin resistance on outcome in patients with Enterobacter bacteremia. METHODS: A total of 183 patients with Enterobacter bacteremia were retrospectively analyzed. Broad-spectrum cephalosporin resistance was defined as in vitro resistance to cefotaxime or ceftazidime. The main outcome measure was the 30-day mortality rate. RESULTS: Of 183 patients, 86 (47%) had bacteremia caused by broad-spectrum cephalosporin-resistant Enterobacter species, and their infections were classified as resistant. The 30-day mortality rate of patients with resistant infections (the resistant group) was significantly higher than that of patients with susceptible infections (the susceptible group) (33.7% vs. 18.6%; P=.021). When the 30-day mortality rates were compared according to the primary sites of infection and underlying conditions, the 30-day mortality rates of the resistant group were significantly higher than those of the susceptible group, in patients with an unknown primary site of infection, or in patients with septic shock. Multivariate analysis showed that broad-spectrum cephalosporin resistance was one of the independent risk factors associated with 30-day mortality (odds ratio [OR], 3.69; 95% confidence interval [CI], 1.01-13.52; P=.049). Presentation with septic shock and an increasing Acute Physiology and Chronic Health Evaluation II score were also independent risk factors for mortality (OR, 59.91 [95% CI, 14.93-240.15; P<.001] and 1.52 [95% CI, 1.24-1.86; P<.001], respectively). CONCLUSIONS: Broad-spectrum cephalosporin resistance adversely affects the outcome of patients with Enterobacter bacteremia, especially those with an unknown primary site of infection and those with septic shock.
Authors: E Velasco; R Byington; C A S Martins; M Schirmer; L M C Dias; V M S C Gonçalves Journal: Eur J Clin Microbiol Infect Dis Date: 2006-01 Impact factor: 3.267
Authors: M Saliba; D Saadeh; F Bouchand; B Davido; C Duran; B Clair; C Lawrence; D Annane; P Denys; J Salomon; L Bernard; A Dinh Journal: Spinal Cord Date: 2016-12-20 Impact factor: 2.772
Authors: Armand Paauw; Jan Verhoef; Ad C Fluit; Hetty E M Blok; Titia E M Hopmans; Annet Troelstra; Maurine A Leverstein-van Hall Journal: J Clin Microbiol Date: 2007-02-21 Impact factor: 5.948
Authors: Markus Hilty; Parham Sendi; Salome N Seiffert; Sara Droz; Vincent Perreten; Andrea M Hujer; Robert A Bonomo; Kathrin Mühlemann; Andrea Endimiani Journal: Int J Antimicrob Agents Date: 2013-01-10 Impact factor: 5.283
Authors: Sun Bean Kim; Yong Duk Jeon; Jung Ho Kim; Jae Kyoung Kim; Hea Won Ann; Heun Choi; Min Hyung Kim; Je Eun Song; Jin Young Ahn; Su Jin Jeong; Nam Su Ku; Sang Hoon Han; Jun Yong Choi; Young Goo Song; June Myung Kim Journal: Yonsei Med J Date: 2015-03 Impact factor: 2.759
Authors: Vikas P Chaubey; Johann D D Pitout; Bruce Dalton; Daniel B Gregson; Terry Ross; Kevin B Laupland Journal: BMC Infect Dis Date: 2014-12-14 Impact factor: 3.090